Oxitril (Duloxetine)

Oxitril is an SNRI that modulates pain and mood pathways in several clinical conditions.

• Major depressive disorder: alleviates depressive symptoms and improves functional outcomes.
• Generalized anxiety disorder: reduces anxiety severity and associated physical symptoms.
• Diabetic peripheral neuropathic pain: lessens pain intensity and improves quality of life.
• Fibromyalgia: decreases widespread pain and fatigue.
• Chronic musculoskeletal pain: provides analgesic benefit in conditions such as chronic low back pain.

• Duloxetine inhibits the reuptake of serotonin and norepinephrine at central nervous system synapses, increasing the extracellular concentrations of these neurotransmitters. The enhanced serotonergic and noradrenergic signaling modulates mood regulation and pain perception pathways, contributing to its antidepressant and analgesic effects.

Adverse reactions to duloxetine may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dry mouth: reduced salivation causing throat discomfort.
• Headache: transient cranial pain.
• Insomnia: difficulty initiating or maintaining sleep.
• Sweating: increased perspiration, especially at night.
• Dizziness: light‑headed sensation, often postural.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or clinically significant liver injury.
• Hypertensive crisis: sudden, severe increase in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, neuromuscular abnormalities.
• Suicidal ideation: emergence or worsening of suicidal thoughts.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmia: QT prolongation or other rhythm disturbances.

When prescribing duloxetine, clinicians should consider several safety aspects.

• Hepatic function: assess liver enzymes before initiating therapy.
• Renal function: adjust dose in patients with severe renal impairment.
• Cardiovascular status: monitor blood pressure and heart rate regularly.
• Psychiatric monitoring: watch for emergence of suicidal thoughts, especially early in treatment.
• Drug discontinuation: taper gradually to reduce withdrawal symptoms.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Duloxetine interacts with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• MAO inhibitors: risk of serotonin syndrome; a 14‑day washout is required.
• Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase duloxetine plasma levels.
• Strong CYP2D6 inhibitors (e.g., paroxetine): can raise duloxetine exposure and toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs and antiplatelet agents: heightened bleeding risk.
• Warfarin: potential increase in INR values.
• Alcohol: may exacerbate hepatotoxicity and CNS depression.
• Antihypertensives: duloxetine can augment blood‑pressure‑lowering effects.
• Other serotonergic agents (e.g., tramadol, triptans): monitor for serotonin syndrome.